研究单位：[1]Department of Infectious Diseases,Tongji Hospital感染科[2]Departmen of infectious disease, Xiangya Hospital, Central-south Universit Changsha, Hunan, China[3]The Second Xiangya Hospital of Central South University Changsha, Hunan, China[4]The First Affiliated Hospital with Nanjing Medical University Nanjing, Jiangsu, China[5]The Second Hospital of Nanjing Nanjing, Jiangsu, China[6]Traditional Chinese Medicine,Xiamen Hospital Shantou, Xiamen, China[7]The first affiliated hospital of Wenzhou medical universtiy Wenzhou, Zhejiang, China[8]The First Affiliated Hospital of College of Medicine, Zhejiang University Zhejiang, Hangzhou, China, Doctor[9]The First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi, China[10]The First Affiliated Hospital of Fujian Medical University Fuzhou, Fujian, China[11]BeiJing YouAn Hospital, Capital Medical University Beijing, Beijing, China
研究目的：
This is a prospective, multicentre observational follow-up study of PegIFN treatment unstained response in nucleoside experienced patients with Chronic Hepatitis B.Patients will join this study after finished following clinical trail about A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B(OSST trail),A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B (COST study), Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients(Endeavor study),A Prospective Clinical Trial in Chronic Hepatitis B Patients Nucleotide Analogues Experienced (Anchor A Study),Sequential/Combination Therapy in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients (NPGV study).We plan to compare the HBsAg negative rate and maintenance rate,the occurrence of liver cirrhosis and the occurrence rate of hepatocellular carcinoma(HCC) related to hepatitis B virus(HBV) within five years between interferon group (including interferon alone or interferon combined with other drugs) and nucleoside analogues.Patients were divided into two groups based on whether they received interferon or not.
